NCT02512003已完成不适用
Pilot Study of the REVA Sirolimus-Eluting Bioresorbable Coronary Scaffold
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 7
- 试验地点
- 2
- 主要终点
- Ischemia-driven Target Lesion Revascularization (TLR)
研究概览
简要总结
The FANTOM I pilot study is intended to assess safety of the Fantom Bioresorbable Coronary Scaffold in native coronary arteries.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has evidence of myocardial ischemia or a positive functional study
- •Patient has a normal CK-MB
- •Target lesion has a visually estimated stenosis of ≥50% and <100%
- •Target lesion is located in a native coronary artery with average reference vessel diameter ≥ 2.7mm and ≤ 3.3mm
- •Target lesion length must be ≤ 14mm
排除标准
- •Patient has experienced a myocardial infarction (CK-MB or Troponin > 5 X ULN) within 72 hours of the procedure
- •Patient has a left ventricular ejection fraction < 25%
- •Patient has unprotected lest main coronary disease with ≥50% stenosis
- •The target vessel is totally occluded (TIMI Flow 0 or 1)
- •Target lesion involves a bifurcation (a lesion with a side branch ≥ 2.0 mm in diameter containing a ≥ 50% stenosis).
- •Target lesion is located within a bypass graft
- •Target lesion has possible or definite thrombus
结局指标
主要结局
Ischemia-driven Target Lesion Revascularization (TLR)
时间窗: 4 months
Percent of Patients with TLR at 4 months
次要结局
- Optical Coherence Tomography (OCT) Imaging on a Subset of Patients(4 months)
- Target Lesion Revascularization (TLR)(12, 24, 36, 48 and 60 months)
- Target Vessel Revascularization(12, 24, 36, 48 and 60 months)
- Procedural Success(30 days)
- Major Adverse Cardiac Events(12, 24, 36, 48 and 60 months)
- Target Vessel Failure (TVF)(12, 24, 36, 48 and 60 months)
- Acute Technical Success(Day 0)
- Quantitative Coronary Angiography (QCA) derived parameters(4 months)
- Intravascular Ultrasound (IVUS) derived parameters(4 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary ScaffoldCoronary Artery DiseaseNCT02539966REVA Medical, Inc.272
Unknown
不适用
NeoVas Bioresorbable Coronary Scaffold Randomized Controlled TrialCoronary Artery DiseaseNCT02305485Lepu Medical Technology (Beijing) Co., Ltd.560
已完成
4 期
Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft VasculopathyCardiac Allograft VasculopathyNCT02377648Universita di Verona34
已完成
不适用
Safety Study of a Bioresorbable Coronary StentCoronary Artery StenosisCoronary DiseaseCoronary RestenosisCardiovascular DiseaseCoronary Artery DiseaseMyocardial IschemiaNCT01262703REVA Medical, Inc.49
Unknown
不适用
NeoVas Bioresorbable Coronary Scaffold Registry StudyCoronary Artery DiseaseNCT02305472Lepu Medical Technology (Beijing) Co., Ltd.825